Durvalumab has been approved as a monotherapy in Switzerland for the treatment of adult patients with unresectable small cell lung cancer (LS-SCLC, limited-stage small cell lung cancer) whose disease has not progressed after platinum-based chemoradiotherapy (CRT) [1]. It offers a new treatment option that has been shown to improve the survival of patients with this aggressive form of lung cancer.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Chronic pain
Nano-ECS modulator Adezunap improves therapy success
- Psoriasis and PsA
Biologics, oral peptide and trivalent nanobody – current results and trends
- Cancer in Europe: facts and analysis
New Health Policy Report published
- Gastrointestinal complaints
PPI regulation under the microscope
- Wound management: clinical diagnostics
Assessing the risk of infection – from the ABCDE to the TILI score
- Study report
Digital patient education for atrial fibrillation shows measurable effects
- New practice guideline for fibromyalgia syndrome
Good times, bad times
- Important basics and studies on cancer and the psyche